Opinion|Videos|June 6, 2024
Real-World Clinical Experience With Ruxolitinib Cream Monotherapy to Manage Atopic Dermatitis
Author(s)Lawrence Eichenfield, MD
In this recently presented poster, a dermatology expert draws on clinical experience to reveal why healthcare providers switch treatments for atopic dermatitis (AD). The expert also examines how these reasons vary with disease stage and patient demographics, offering nuanced insights into AD management.
Advertisement
Episodes in this series
- In your experience, what are the most commonly cited reasons by healthcare providers for switching treatments in patients with AD?
- In your experience, how might these factors vary across different stages of the disease or patient populations?
- How do you interpret the implications of the majority of patients experiencing improved disease control upon transitioning to ruxolitinib cream, particularly concerning disease management strategies and patient outcomes?
Advertisement
Related to this article
A single subcutaneous dose led to a 4-point or greater itch reduction in 82% of patients with chronic pruritus at week 12 vs 22% with placebo, Attovia reported.
Pediatric dermatologists outline how to evaluate suspected topical steroid withdrawal, exclude mimics, and preserve family trust in eczema care.
Diego Ruiz Dasilva, MD, and Lindsey Finklea, MD, discuss the burden of chronic inducible urticaria and phase 3 remIND findings for remibrutinib.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Advertisement
Advertisement
Trending on Dermatology Times
1
Don't Be Rash: Navigating Topical Steroid Withdrawal Concerns in Pediatric Eczema
2
AADA Warns of 6% Medicare Payment Cut for Dermatologists in 2027
3
ATTO-1310 Reduces Itch at Week 12 in Chronic Pruritus and Atopic Dermatitis
4
Where Patients With Alopecia Areata Fit on the Path to Systemic Treatment
5